Pharming Group (PHAR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.06
- Surprise
- -96.8%
- Revenue (period 2026-06-30)
- $90.2M
- Score today
- 6.3/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAR Hold at 6.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -96.8% surprise compares with a -372.6% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Overbought (RSI 76)
- Below 200-MA, MA slope -7.0%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.15
- Price target
- $29.20
- Stop
- $11.30
- Upside to target
- +140.3%
- Reward-to-risk
- 9.3:1
Forward estimates sit below the trailing run-rate (68.1× forward vs 38.3× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
PHAR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $867.7M
- P/E (fwd)
- 68.1
- P/E (ttm)
- 38.3
- 52-week range
- $9.11–$21.34
- Off 52-week high
- 43.1%
- RSI (14)
- 76
- Volume vs avg
- 0.11×
- Score today
- 6.3/10